Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PhRMA Embraces Teva Across Brand-Generic Divide

Executive Summary

PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.


Related Content

Teva, Allergan Probably Won't Need More Divestments To Get FTC Approval
For Generics Industry, Will Larger Firms Mean Weaker Lobbying?
Biosimilars Forum: How Do You Create A Brand-Generic Coalition? Don’t Talk About Naming
Teva Extends Diversification To Lobbying, Not Just Product Mix; Seeks To Join BIO
Teva Resigning From GPhA: Diversification, Size Led Firm's Priorities In Different Direction


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst